Sign up to save your podcasts
Or
Share Flavia Castelino, MD / Sonye K. Danoff, MD, PhD - The Evolving Treatment Landscape of SSc-ILD: Strategies to Improve Recognition and Management
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Flavia Castelino, MD / Sonye K. Danoff, MD, PhD - The Evolving Treatment Landscape of SSc-ILD: Strategies to Improve Recognition and Management
Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.
View all episodes
By PVI, PeerView Institute for Medical Education
5
33 ratings
Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.
More shows like PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
27 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
10 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners